English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/108791
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

G1/S cell cycle checkpoint dysfunction in lymphoblasts from sporadic Parkinson’s disease patients.

AuthorsEsteras, Noemí ; Alquézar, Carolina ; Bartolomé Robledo, Fernando ; De la Encarnación, Ana; Bermejo-Pareja, Félix; Molina, J.A.; Martín-Requero, Ángeles
KeywordsParkinson disease
Lymphocytes
Cell cycle
pRb
CDK6
TDP-43
Cyclin D3
Rapamycin
Sodium butyrate
PD-332991
Issue Date3-Sep-2014
PublisherHumana Press
CitationMolecular Neurobiology, 2014
AbstractParkinson’s disease (PD) is the second most prevalent neurodegenerative disease among aging individuals, affecting greatly the quality of their life. However, the pathogenesis of Parkinson's disease is still incompletely understood to date. Increasing experimental evidence suggests that cell cycle reentry of postmitotic neurons precedes many instances of neuronal death. Since cell cycle dysfunction is not restricted to neurons, we investigated this issue in peripheral cells from patients suffering from sporadic PD and age-matched control individuals. Here, we describe increased cell cycle activity in immortalized lymphocytes from PD patients, that is associated to enhanced activity of the cyclin D3/CDK6 complex, resulting in higher phosphorylation of the pRb family protein and thus, in a G1/S regulatory failure. Decreased degradation of cyclin D3, together with increased p21 degradation, as well as elevated levels of CDK6 mRNA and protein were found in PD lymphoblasts. Inhibitors of cyclin D3/CDK6 activity like sodium butyrate, PD-332991, and rapamycin were able to restore the response of PD cells to serum stimulation. We conclude that lymphoblasts from PD patients are a suitable model to investigate cell biochemical aspects of this disease. It is suggested that cyclin D3/CDK6-associated kinase activity could be potentially a novel therapeutic target for the treatment of PD.
Description38 p.-8 fig.
Publisher version (URL)http://dx.doi.org/10.1007/s12035-014-8870-y
URIhttp://hdl.handle.net/10261/108791
DOI10.1007/s12035-014-8870-y
ISSN0893-7648
E-ISSN1559-1182
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
MOLN 2014, Martín-Requero.pdf2 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.